Daewoong and AstraZeneca will terminate a joint sales contract for Nexium, a PPI-based gastroesophageal reflux disease treatment. The new joint sales partner of the large item, which generated about 50 billion won in sales last year, is said to be likely to be Ildong.

According to the pharmaceutical industry on the 9th, Daewoong and AstraZeneca agreed to terminate the joint sales contract of Nexium last month. The contract is until December 31 this year.

Nexium is a PPI-based gastroesophageal reflux disease treatment launched in Korea in 2000. Daewoong has been jointly selling with AstraZeneca since 2008. Sales have steadily increased over the next 14 years, making it the No. 1 item in t